Pharmacotherapy of atopic dermatitis: a comparison of clinical response with Lebrikizumab and Tezepelumab

Atopic dermatitis is a disease that affects millions worldwide. Research indicates that people suffering from atopic dermatitis respond well to monoclonal antibody treatment aimed at characteristic immune cell markers. By targeting immune cell markers, the immune system is subsequently suppressed in a way such that disease activity is decreased. Monoclonal antibody treatments targeted towards a variety of immune cell markers have historically been shown to result in decreases in atopic dermatitis disease activity. Many studies have assessed disease activity with monoclonal antibody treatments, but few have compared different treatments. A systematic review of a study that assessed the disease activity for those taking tezepelumab was then compared to the findings of another study which assessed the disease activity with those taking lebrikizumab. The patients treated with tezepelumab had significantly decreased atopic dermatitis activity when compared with other matched controls. Those who were treated with lebrikizumab had significantly decreased disease activity when compared with other matched controls. However, those who were treated with lebrikizumab had a greater reduction of disease activity as compared to control groups than did those who were treated with lebrikizumab. Monoclonal antibody treatments for atopic dermatitis are widespread. It is critical that these treatments are compared in order to find those with the greatest efficacy. For this review, lebrikizumab seemed to have a greater reduction of disease activity than did tezepelumab. Further studies with greater sample sizes are needed to conclude which has greater efficacy